LUNGevity Foundation (@lungevity) 's Twitter Profile
LUNGevity Foundation

@lungevity

LUNGevity, the nation’s leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.

ID: 15486468

linkhttp://www.lungevity.org calendar_today18-07-2008 21:11:22

30,30K Tweet

32,32K Followers

1,1K Following

LUNGevity Foundation (@lungevity) 's Twitter Profile Photo
LUNGevity Foundation
@lungevity

a month ago

Ph1 trial of zoldonrasib (RMC-9805), an oral KRAS G12D inhibitor in pts w/ #NSCLC showed ORR of 61%. Side effects primarily gastro-intestinal. Great to see new options for this pt group. Kathryn C. Arbour Memorial Sloan Kettering Cancer Center #AACR25 KRASKickers

Ph1 trial of zoldonrasib (RMC-9805), an oral KRAS G12D inhibitor in pts w/ #NSCLC showed ORR of 61%. Side effects primarily gastro-intestinal. Great to see new options for this pt group. <a href="/KCArbourMD/">Kathryn C. Arbour</a> <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> #AACR25 <a href="/KRASKickers/">KRASKickers</a>